MyChesCo on MSN
China Clears IND for SEED Therapeutics’ First-in-Class Cancer Drug in Global Trial Push
SEED Therapeutics announced that China’s National Medical Products Administration has cleared the Investigational New Drug ...
YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today ...
OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...
The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in ...
On November 13, 2025, effective November 14, 2025 the Securities and Exchange Commission (“Commission”), in Administrative Proceeding File No. 3-22541, in Release No. 104178 issued an Order Making ...
TipRanks on MSN
Dermata Therapeutics Ends License Agreement with Villani
An update from Dermata Therapeutics ( ($DRMA) ) is now available. On November 17, 2025, Dermata Therapeutics announced the termination of its ...
An analysis of federal data shows a pronounced decline, despite alarming conditions found at some manufacturers.
Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback